Have a feature idea you'd love to see implemented?
Let us know!
CASI CASI Pharmaceuticals Inc
Price (delayed)
$5.25
Market cap
$80.3M
P/E Ratio
N/A
Dividend/share
N/A
EPS
N/A
Enterprise value
$82.88M
CASI Pharmaceuticals, Inc. is a U.S. biopharmaceutical company focused on developing and commercializing innovative therapeutics and pharmaceutical products in China, the United States, and throughout the world. The Company is
Highlights
The equity has soared by 53% since the previous quarter but it has dropped by 52% year-on-year
CASI Pharmaceuticals's quick ratio has decreased by 46% YoY
The debt has increased by 3.6% since the previous quarter
Key stats
What are the main financial stats of CASI
Market
Valuations
Earnings
Shares outstanding
15.29M
Market cap
$80.3M
Enterprise value
$82.88M
Price to earnings (P/E)
N/A
Price to book (P/B)
5.13
Price to sales (P/S)
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
Revenue
N/A
EBIT
N/A
EBITDA
N/A
Free cash flow
N/A
Per share
Balance sheet
Liquidity
EPS
N/A
Free cash flow per share
N/A
Book value per share
$1.02
Revenue per share
N/A
TBVPS
$4.09
Total assets
$63.62M
Total liabilities
$49.77M
Debt
$19.12M
Equity
$13.85M
Working capital
$32.41M
Debt to equity
1.38
Current ratio
3.2
Quick ratio
2.17
Net debt/EBITDA
N/A
Margins
Efficiency
Dividend
EBITDA margin
N/A
Gross margin
N/A
Net margin
N/A
Operating margin
N/A
Return on assets
N/A
Return on equity
N/A
Return on invested capital
N/A
Return on capital employed
N/A
Return on sales
N/A
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
CASI stock price
How has the CASI Pharmaceuticals stock price performed over time
Intraday
-0.19%
1 week
-10.71%
1 month
-4.55%
1 year
-7.89%
YTD
-26.68%
QTD
-14.77%
Financial performance
How have CASI Pharmaceuticals's revenue and profit performed over time
Revenue
N/A
Gross profit
N/A
Operating income
N/A
Net income
N/A
Gross margin
N/A
Net margin
N/A
Growth
What is CASI Pharmaceuticals's growth rate over time
Valuation
What is CASI Pharmaceuticals stock price valuation
P/E
N/A
P/B
5.13
P/S
N/A
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
N/A
The stock's P/B is 90% above its 5-year quarterly average of 2.7 and 7% above its last 4 quarters average of 4.8
The equity has soared by 53% since the previous quarter but it has dropped by 52% year-on-year
Efficiency
How efficient is CASI Pharmaceuticals business performance
Dividends
What is CASI's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for CASI.
Financial health
How did CASI Pharmaceuticals financials performed over time
The total assets is 28% greater than the total liabilities
CASI's total liabilities has soared by 109% YoY and by 18% from the previous quarter
CASI Pharmaceuticals's quick ratio has decreased by 46% YoY
The debt is 38% greater than the equity
The equity has soared by 53% since the previous quarter but it has dropped by 52% year-on-year
CASI's debt to equity is down by 33% QoQ
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise
specified. Data from 
and Sharadar.